Highlights Propanc Biopharma, Inc.

Stocks

PPCB

US74346N8002

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:57:27 11/06/2026 BST			5-day change	1st Jan Change
3.305 ^USD	+127.93%		-11.31%	-89.19%

04:39pm	Propanc Biopharma, Inc. authorizes a Buyback Plan.	CI
04:37pm	Propanc Biopharma, Inc. announces an Equity Buyback for $5 million worth of its shares.	CI

Highlights

04:39pm	Propanc Biopharma, Inc. authorizes a Buyback Plan.	CI
04:37pm	Propanc Biopharma, Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
03:10pm	Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump	MT
05-20	Propanc Biopharma, Inc. Plans Clinical Trial Application for PRP in Advanced Cancer Patients	CI
05-19	Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1B, FIH Study in Advanced Cancer Patients	CI
05-14	Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
04-10	Propanc Biopharma Inc - files to offer resale of up to 15 million shares of common stock by selling stockholder - SEC filing	RE
03-24	Propanc Biopharma Inc Establishes Multi-Year Joint Research Collaboration Agreement with the Universities of Jaén and Granada Spain	CI
03-12	Propanc Biopharma, Inc. Targets Pancreatic Cancer Market With PRP Proenzyme Therapy	CI
03-03	Propanc Biopharma, Inc. Highlights Lead Asset PRP As Novel Therapeutic Approach For Metastatic Cancer	CI
02-17	Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
02-05	Propanc Biopharma, Inc. Unveils Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market	CI
01-20	Propanc Biopharma, Inc. Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia	CI
01-15	Propanc Biopharma, Inc. Announces the Latest Update on Pancreatic Cancer Research	CI
12-30	Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholder - SEC filing	RE
12-04	Propanc Biopharma, Inc. Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs	CI
11-17	Propanc Biopharma provides corporate update and reports first quarter 2025/26 results	RE
11-14	Propanc Biopharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2025	CI
11-04	Propanc Biopharma pursues strategic acquisition of DAT firms trading below market cap to net asset value	RE
29/09/25	Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2025	CI
17/09/25	Propanc Biopharma, Inc. Receives Certificate of Grant for "Proenzyme Composition" Patent from US Patent & Trademark Office	CI
15/08/25	Propanc Biopharma announces Nasdaq uplisting and pricing of $4 million public offering	RE
14/08/25	Propanc Biopharma, Inc. has completed an IPO in the amount of $4 million.	CI
15/05/25	Propanc Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2025	CI
14/02/25	Propanc Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2024	CI